EUVIMEDEUVIMED entdecken
Open Access

Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis

David Massicotte-Azarniouch iD, Randal K Detwiler, Yichun Hu, Ronald J Falk, Manish K Saha, Susan L Hogan, Vimal K Derebail

Nephrology Dialysis Transplantation · 31.08.2023 · 38 (9) · 2009-2018

DOI: 10.1093/ndt/gfac337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 22.12.2022. Verfasst von David Massicotte-Azarniouch und 6 weiteren Autor:innen. Beteiligte Einrichtung: UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Glomerulonephritis, Neoplasms, Lymphoproliferative Disorders. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Kidney transplant patients with glomerulonephritis (GN) as their native disease may receive significant amounts of pre-transplant immunosuppression (PTI), which could increase the risk for development of malignancy post-transplant.

Methods

We conducted a single-center, retrospective study of kidney transplant recipients from January 2005 until May 2020. Patients with GN as their native kidney disease who received PTI for treatment of GN (n = 184) were compared with a control cohort (n = 579) of non-diabetic, non-PTI-receiving kidney transplant patients. We calculated hazard ratios (HR) with 95% confidence intervals (95% CI) for outcomes of first occurrence of solid or hematologic malignancy, non-melanoma skin cancer (NMSC) and post-transplant lymphoproliferative disorder (PTLD).

Results

Over a median follow-up of 5.7 years, PTI for GN was associated with significantly increased risk for malignancy compared with controls [13.0% vs 9.7%, respectively; adjusted HR 1.82 (95% CI 1.10–3.00)], but not for NMSC [10.3% vs 11.4%, respectively; adjusted HR 1.09 (95% CI 0.64–1.83)] or PTLD [3.3% vs 3.1%, respectively; adjusted HR 1.02 (95% CI 0.40–2.61)]. The risk for malignancy was significantly increased in those who received cyclophosphamide [HR 2.59 (95% CI 1.48–4.55)] or rituximab [HR 3.82 (95% CI 1.69–8.65)] pre-transplant, and particularly in those who received both cyclophosphamide and rituximab, but not for calcineurin inhibitors or mycophenolate.

Conclusion

The use of PTI for treatment of GN, especially cyclophosphamide or even with rituximab, is associated with increased risk for development of solid or hematologic malignancy post-transplant. These data highlight potential risks with treatment of GN and underscore the importance of post-transplant malignancy surveillance in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationGlomerulonephritisNeoplasmsLymphoproliferative DisordersHematologic NeoplasmsHumansRetrospective StudiesRituximabImmunosuppression TherapyCyclophosphamideTransplant RecipientsRisk Factors

Stichwörter der Autor:innen

glomerulonephritisimmunosuppressionkidney transplantmalignancynon-melanomatous skin cancer

Substanzen

RituximabCyclophosphamide

Autor:innen und Institutionen

  • UNC Kidney Center, Division of Nephrology and Hypertension, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

ORCID-Profile: David Massicotte-Azarniouch

Förderung

  • NIDDK NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Massicotte-Azarniouch, D., Detwiler, R. K., Hu, Y., Falk, R. J., Saha, M. K., Hogan, S. L., & Derebail, V. K. (2023). Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis. Nephrology Dialysis Transplantation, 38(9), 2009-2018. https://doi.org/10.1093/ndt/gfac337

Vancouver

Massicotte-Azarniouch D, Detwiler RK, Hu Y, Falk RJ, Saha MK, Hogan SL, et al. Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis. Nephrology Dialysis Transplantation. 2023;38(9):2009-2018. doi:10.1093/ndt/gfac337

BibTeX
@article{MassicotteAzarniouch2023,
  author = {Massicotte-Azarniouch, David and Detwiler, Randal K and Hu, Yichun and Falk, Ronald J and Saha, Manish K and Hogan, Susan L and Derebail, Vimal K},
  title = {Malignancy risk in kidney transplant recipients exposed to immunosuppression pre-transplant for the treatment of glomerulonephritis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {9},
  pages = {2009--2018},
  doi = {10.1093/ndt/gfac337}
}
Kostenlos starten →